Sitemap > Breaking Research > Metabolic & Hormonal Disorders
Displaying 201 - 250 of 3753 results
- Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
- Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study.
- Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials.
- Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice.
- [Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset]
- Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus.
- Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
- Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model.
- Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model.
- Adenovirus-mediated high expression of resistin causes dyslipidemia in mice.
- Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.
- Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms.
- Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: omega-piperidinoalkanamine derivatives.
- Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.
- Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes.
- Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.
- Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors.
- Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors.
- Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists.
- Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor.
- Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin.
- Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
- Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol.
- Enhanced insulin sensitivity, energy expenditure and thermogenesis in adipose-specific Pten suppression in mice.
- Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin.
- Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans.
- Double transgenic mice with type 1 diabetes mellitus develop somatic, metabolic and vascular disorders.
- Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy.
- Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes.
- Synthesis and protein conjugation studies of vitamin K analogues.
- 2-(4-Methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl)benzamide activates Kir6.2/SUR1 K(ATP) channels.
- Synthesis and biological evaluation of an orally active ghrelin agonist that stimulates food consumption and adiposity in rats.
- 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.
- Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
- Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes.
- Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the insulin resistance atherosclerosis study (IRAS) family study.
- Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus.
- Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes.
- Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
- Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats.
- HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
- Structural characterization and pharmacology of a potent (Cys101-Cys119, Cys110-Cys117) bicyclic agouti-related protein (AGRP) melanocortin receptor antagonist.
- Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.
- Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.
- Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
- Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
- Improved survival of microencapsulated islets during in vitro culture and enhanced metabolic function following transplantation.
- Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
- The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 Next >